Current stock page

Catalysts

PGEN Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

PGENPrecigen, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$4.54−$0.12 (−2.58%)

Latest quote

  • Momentum
    55
  • Value
    63
  • Quality
    60
  • Risk resilience
    31
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 2, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 55/100

Momentum 55/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 6.54%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 55/100AIQ Edge 5/10 In Line With Peers
Beat rate
63%
5 of 8 reported periods
Average surprise
-91.1%
Across covered historical reports
Latest result
+33.3%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—$0.06$0.08+33.3%$71.55M$74.15M
Aug 4, 2026—-$0.01$0.05+514.3%$27.98M$54.98M
May 13, 2026—-$0.03-$0.02+33.3%$20.81M$23.25M
Mar 25, 2026—-$0.10-$0.07+33.6%$8.42M$4.58M
Nov 13, 2025—-$0.08-$1.06-1225.0%$500K$2.92M
Aug 12, 2025—-$0.09-$0.11-26.9%$952K$878K
May 14, 2025—-$0.08-$0.18-125.0%$650K$1.34M
Mar 19, 2025—-$0.06-$0.04+33.3%$3.03M$1.19M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
3
Buy
1
Hold
12-month analyst target
$12.00
+164.32% versus current price
Based on 4 analyst observations. Targets are estimates, not predictions.
Low target
$12.00
+164.32% vs latest price
Average target
$12.00
+164.32% vs latest price
High target
$12.00
+164.32% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 2, 2027

Next known earnings or reporting date.

EPS estimate$0.11

Current analyst expectation for the upcoming report.

Revenue estimate$89.01M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score55

Where event reaction would show up first.

AIQ score55/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
4
Average target
$12.00
Target upside
164.32%
Target range
$12.00 - $12.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
1
Negative
2
zacks.com · Nov 4, 2026

Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates

Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and -1.70%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

rttnews.com · Nov 2, 2026

Morning Market Movers: CLRO, PERI, PGEN, SVRN See Big Swings

Amidst U.S. stock futures pointing higher, premarket trading on Monday morning is seeing notable activity in several stocks, particularly CLRO, PERI, PGEN and SVRN.

gurufocus.com · Sep 25, 2026

PGEN Initiates Coverage On B. Riley Securities -- Rating Set to Buy

On September 25, 2026, B. Riley Securities initiated coverage on Precigen (PGEN) with a Buy rating. The firm announced a price target of $12.00 for the stock.

gurufocus.com · Sep 21, 2026

PGEN Looks 47.9% Undervalued on GF Value™ Despite Financial Challenges

On September 21, 2026, Precigen Inc (NASDAQ: PGEN) announced that the U.S. Food and Drug Administration (FDA) has officially designated its AdenoVerse immunothe

gurufocus.com · Aug 29, 2026

Precigen (PGEN) Director Jeffrey Kindler Sells 185,000 Shares

Director Jeffrey Kindler sold 185,000 shares of Precigen Inc (PGEN) on August 26, 2026, according to a recent SEC Filing. Following this transaction, the inside

Open full news and sentiment

PGEN Catalysts FAQ

What are the next catalysts for PGEN stock?

PGEN's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move PGEN stock?

Upcoming events that could move PGEN include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could PGEN's next earnings report affect the stock?

PGEN's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive PGEN stock higher?

PGEN could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt PGEN stock?

PGEN could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.